This company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsDMK Pharmaceuticals（0A4X）株式概要DMKファーマシューティカルズ株式会社は、臨床段階のニューロ・バイオテクノロジー企業で、アレルギー、オピオイド過剰摂取、呼吸器、炎症性疾患の治療分野における製品の開発と商業化を進めている。 詳細0A4X ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性1/6配当金0/6報酬過去 1 年間で収益は150.3%増加しましたリスク分析マイナスの株主資本 意味のある時価総額がありません ( $10 )株式の流動性は非常に低い 最新の財務報告は1年以上前のものである +1 さらなるリスクすべてのリスクチェックを見る0A4X Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW491,113 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG491,113 investors already sharing narrativesYour Fair ValueUS$Current PriceUS$0.000999.9% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-39m21m2016201920222025202620282031Revenue US$3.6mEarnings US$527.2kAdvancedSet Fair ValueView all narrativesDMK Pharmaceuticals Corporation 競合他社NVN LiquidationSymbol: OTCPK:NOVN.QMarket cap: US$28.0PLx Pharma WinddownSymbol: OTCPK:PLXP.QMarket cap: US$30.0Baudax BioSymbol: OTCPK:BXRX.QMarket cap: US$52.0RVL PharmaceuticalsSymbol: OTCPK:RVLP.QMarket cap: US$111.0価格と性能株価の高値、安値、推移の概要DMK Pharmaceuticals過去の株価現在の株価US$0.000952週高値US$1.0352週安値US$0.0001ベータ1.351ヶ月の変化0%3ヶ月変化-93.02%1年変化-99.82%3年間の変化-100.00%5年間の変化n/aIPOからの変化-100.00%最新ニュースお知らせ • Sep 10Second Motion for Exclusivity Period Extension Approved For DMK Pharmaceuticals CorporationThe US Bankruptcy Court granted an order for the extension of the exclusivity period DMK Pharmaceuticals Corporation on September 9, 2024. As per the order, the debtor’s exclusivity period to solicit votes on its plan has been extended by 30 days i.e. up to October 31, 2024.お知らせ • Aug 03Joint Liquidation Plan and Disclosure Statement Filed by DMK Pharmaceuticals CorporationDMK Pharmaceuticals Corporation, along with its affiliates, filed a joint plan of liquidation with related disclosure statement in the US Bankruptcy Court on August 2, 2024. As per the plan filed, administrative expense claims, fee claims, priority tax claims, U.S. Trustee fees, and priority non-tax claims of $979 shall be paid in full in cash. Allowed secured claims are of $0. Allowed unsecured claims of $25.34 million shall be recovered 3.4% i.e., $0.86 million pro rata share of distributions from liquidation trust assets as beneficiaries of the liquidation trust until they have received payment in full. Subordinated claims of $16.96 million shall not receive or retain any distribution under the plan. Equity interests will be extinguished on the effective date and shall not receive or retain any distribution under the plan. The plan shall be funded by the liquidation trust assets, other than the professional fees reserve. on the effective date, the debtors shall fund the professional fees reserve in full in cash.お知らせ • Jun 15First Motion for Exclusivity Period Extension Approved For DMK Pharmaceuticals CorporationThe US Bankruptcy Court granted first order for the extension of the exclusivity periods for DMK Pharmaceuticals Corporation on June 14, 2024. As per the order, the debtor’s exclusivity period to file its plan and to solicit votes on its plan, have been extended by 60 days i.e., up to August 2, 2024, and October 1, 2024, respectively.お知らせ • May 09Motion for Asset Sale Approved for DMK Pharmaceuticals CorporationThe US Bankruptcy Court gave an order approving the sale of substantially all the assets of DMK Pharmaceuticals Corporation on May 8, 2024. The debtor has been authorized to sell substantially all its assets to Zmi Management Inc for a purchase price of $3.17 million in cash. David R. Eastlake and Hans E. Biebl of Greenberg Traurig, LLP acted as legal advisors to the buyer.お知らせ • Mar 22Nasdaq to Delist Common Stock of DMK PharmaceuticalsNasdaq announced that it will delist the common stock of DMK Pharmaceuticals Corporation. DMK Pharmaceuticals’s securities were suspended on February 7, 2024, and have not traded on Nasdaq since that time.お知らせ • Feb 08DMK Pharmaceuticals Corporation(NasdaqCM:DMK) dropped from S&P TMI IndexDMK Pharmaceuticals Corporation(NasdaqCM:DMK) dropped from S&P TMI Index最新情報をもっと見るRecent updatesお知らせ • Sep 10Second Motion for Exclusivity Period Extension Approved For DMK Pharmaceuticals CorporationThe US Bankruptcy Court granted an order for the extension of the exclusivity period DMK Pharmaceuticals Corporation on September 9, 2024. As per the order, the debtor’s exclusivity period to solicit votes on its plan has been extended by 30 days i.e. up to October 31, 2024.お知らせ • Aug 03Joint Liquidation Plan and Disclosure Statement Filed by DMK Pharmaceuticals CorporationDMK Pharmaceuticals Corporation, along with its affiliates, filed a joint plan of liquidation with related disclosure statement in the US Bankruptcy Court on August 2, 2024. As per the plan filed, administrative expense claims, fee claims, priority tax claims, U.S. Trustee fees, and priority non-tax claims of $979 shall be paid in full in cash. Allowed secured claims are of $0. Allowed unsecured claims of $25.34 million shall be recovered 3.4% i.e., $0.86 million pro rata share of distributions from liquidation trust assets as beneficiaries of the liquidation trust until they have received payment in full. Subordinated claims of $16.96 million shall not receive or retain any distribution under the plan. Equity interests will be extinguished on the effective date and shall not receive or retain any distribution under the plan. The plan shall be funded by the liquidation trust assets, other than the professional fees reserve. on the effective date, the debtors shall fund the professional fees reserve in full in cash.お知らせ • Jun 15First Motion for Exclusivity Period Extension Approved For DMK Pharmaceuticals CorporationThe US Bankruptcy Court granted first order for the extension of the exclusivity periods for DMK Pharmaceuticals Corporation on June 14, 2024. As per the order, the debtor’s exclusivity period to file its plan and to solicit votes on its plan, have been extended by 60 days i.e., up to August 2, 2024, and October 1, 2024, respectively.お知らせ • May 09Motion for Asset Sale Approved for DMK Pharmaceuticals CorporationThe US Bankruptcy Court gave an order approving the sale of substantially all the assets of DMK Pharmaceuticals Corporation on May 8, 2024. The debtor has been authorized to sell substantially all its assets to Zmi Management Inc for a purchase price of $3.17 million in cash. David R. Eastlake and Hans E. Biebl of Greenberg Traurig, LLP acted as legal advisors to the buyer.お知らせ • Mar 22Nasdaq to Delist Common Stock of DMK PharmaceuticalsNasdaq announced that it will delist the common stock of DMK Pharmaceuticals Corporation. DMK Pharmaceuticals’s securities were suspended on February 7, 2024, and have not traded on Nasdaq since that time.お知らせ • Feb 08DMK Pharmaceuticals Corporation(NasdaqCM:DMK) dropped from S&P TMI IndexDMK Pharmaceuticals Corporation(NasdaqCM:DMK) dropped from S&P TMI Indexお知らせ • Feb 07DMK Pharmaceuticals Corporation(OTCPK:DMKP.Q) dropped from NASDAQ Composite IndexDMK Pharmaceuticals Corporation has been dropped from Nasdaq Composite Index.お知らせ • Jan 06DMK Pharmaceuticals Corporation, Annual General Meeting, Jan 25, 2024DMK Pharmaceuticals Corporation, Annual General Meeting, Jan 25, 2024, at 09:00 Pacific Standard Time.お知らせ • Nov 29DMK Pharmaceuticals Corporation Regains Full Rights from US WorldMeds for SYMJEPIDMK Pharmaceuticals Corporation announced that it is reacquiring the rights to its SYMJEPI (epinephrine) Injection 0.3mg and SYMJEPI (epinephrine) Injection 0.15mg products from USWM, LLC (“USWM” or “US WorldMeds”). US WorldMeds previously held exclusive distribution and commercialization rights for SYMJEPI and ZIMHI (naloxone) products in the United States, and was responsible for marketing, promotion and distribution efforts. The Company is now actively seeking out-license opportunities for SYMJEPI in the US and globally, in addition to exploring other options with a focus on maximizing value for shareholders.お知らせ • Nov 22Adamis Pharmaceuticals Corporation(NasdaqCM:ADMP) dropped from NASDAQ Composite IndexAdamis Pharmaceuticals Corporation has been dropped from NASDAQ Composite Index.お知らせ • Oct 21DMK Pharmaceuticals Corporation Receives a Superseding Notice from the Listing Qualifications Department of the Nasdaq Stock MarketOn October 18, 2023, DMK Pharmaceuticals Corporation received a superseding notice from the Staff, indicating that the Prior Notice was issued in error. The Subsequent Notice indicated that because the Company was subject to a one-year Mandatory Panel Monitor as a result of a prior hearing before the Panel, the Company was not eligible for the automatic 180-day compliance grace period provided by Listing Rule 5810(c)(3)(A) and that the Company's non-compliance with the Bid Price Rule serves as an additional basis for delisting from Nasdaq. At the hearing, the Company will address its plan to regain compliance with both the Bid Price Rule and the MVLS Rule as well as its continued compliance with all other applicable criteria for continued listing on The Nasdaq Capital Market. There can be no assurance, however, that the Panel will grant the Company's request for continued listing or that the Company will evidence compliance with the listing rules prior to the expiration of any extension that may be granted by the Panel following the hearing.お知らせ • Oct 20+ 1 more updateDMK Pharmaceuticals Corporation Announces CFO ChangesDMK Pharmaceuticals Corporation announced a series of management changes to optimize its leadership structure. Seth Cohen has been appointed as Chief Financial Officer and John Dorbin will assume the position of General Counsel Corporate Secretary. Mr. Cohen will be succeeding the outgoing interim CFO and President and Chief Operating Officer, David Marguglio. These organizational changes will be effective immediately. The new team is tasked with operating a lean and effective organization committed to increasing the sales of DMK’s existing commercial products and advancing its clinical pipeline. Mr. Cohen has over thirty years of experience in business and finance. Since 2011, Mr. Cohen has been a principal at CFOX Consulting, LLC, an advisory firm that specializes in CFO and related services for public, private equity backed, and start-up businesses. From 2000 to 2011, Mr. Cohen served in various leadership roles of increasing responsibility at Newtek Business Services Inc. In 2007, he was appointed CFO and tasked with directing the corporate accounting and finance department as well as overseeing the company’s various subsidiaries. Prior to that, Mr. Cohen served as Director of the Mayor’s Office of Pensions and Public Finance for the City of New York where he managed the securitization of assets, oversaw multibillion-dollar debt issuances, and initiated and helped oversee pension policy. As a trustee for the City of New York’s five pension systems, Mr. Cohen oversaw $100 billion in assets. He developed his corporate and municipal finance skills at Lehman Brothers, Patricof & Co., and Dean Witter Reynolds Inc. Mr. Cohen holds an MBA from Columbia Business School and a B.A. from Yale University.お知らせ • Oct 18DMK Pharmaceuticals Corporation Receives Notice from the Listing Qualifications Staff of the Nasdaq Stock MarketAs previously disclosed, on April 12, 2023, DMK Pharmaceuticals Corporation received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC stating that the market value of the Company’s common stock closed below the minimum $35 million threshold required by Nasdaq Listing Rule 5550(b)(2) for the previous 30 consecutive trading days and, in accordance with the Nasdaq Listing Rules, the Company was provided 180 calendar days, or until October 9, 2023, to regain compliance with the Rule. On October 11, 2023, the Company received notice from the Staff that the Company’s common stock was subject to delisting unless the Company timely requests a hearing before the Nasdaq Hearings Panel. The Company plans to timely request a hearing before the Panel, which request will stay any further action by Nasdaq at least until the hearing is held and any extension the Panel may grant to the Company following the hearing expires. There can be no assurance, however, that the Panel will grant the Company’s request for continued listing or that the Company will regain compliance with the Rule prior to the expiration of any extension that may be granted to the Company following the hearing.お知らせ • Oct 11DMK Pharmaceuticals Receives Notice from the Listing Qualifications Department of the Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price RequirementsOn October 4, 2023, DMK Pharmaceuticals Corporation received a notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that it is not in compliance with the $1.00 minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”) for continued listing on The Nasdaq Capital Market. Based on the closing bid price of the Company’s common stock for at least 30 consecutive business days before receipt of the Notice, the Company no longer meets the minimum bid price requirement of the Rule. This notice has no immediate effect on the Company’s Nasdaq listing or the trading of its common stock. The Notice indicated that the Nasdaq Listing Rules provide the Company a compliance period of 180 calendar days from the date of the Notice, or until April 1, 2024, to regain compliance, pursuant to Listing Rule 5810(c)(3)(A). The Notice stated that if at any time during the compliance period the bid price of the Company’s common stock closes at or above $1.00 per share for a minimum of 10 consecutive business days, the Staff will provide written notification that the Company has achieved compliance with the minimum bid price requirement, and the matter would be resolved. The Notice also stated that if the Company does not regain compliance within the initial compliance period, it may be eligible for an additional 180-day compliance period. To qualify for additional time, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and would need to provide written notice of its intention to cure the deficiency during the second compliance period. The Notice stated that if the Company meets these requirements, Nasdaq will inform the Company that it has been granted an additional 180 calendar days to regain compliance. The Notice also stated that if it appears to the Staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, the Staff would notify the Company that it will not be granted additional 180 days for compliance and will be subject to delisting at that time. In the event of such notification, the Company may appeal the Staff’s determination to delist its securities, but there can be no assurance that any such appeal would be successful. There are no assurances that the Company will be able to regain compliance with the Rule or will otherwise be in compliance with other Nasdaq listing requirements.お知らせ • Sep 02Adamis Pharmaceuticals Corporation, Annual General Meeting, Nov 09, 2023Adamis Pharmaceuticals Corporation, Annual General Meeting, Nov 09, 2023.お知らせ • Aug 06Adamis Pharmaceuticals Corporation has completed a Composite Units Offering in the amount of $8.005387 million.Adamis Pharmaceuticals Corporation has completed a Composite Units Offering in the amount of $8.005387 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 4,800,000 Price\Range: $1.35 Discount Per Security: $0.0945 Security Name: Pre-Funded Units Security Type: Equity/Derivative Unit Securities Offered: 1,130,000 Price\Range: $1.3499 Discount Per Security: $0.09449お知らせ • Jul 26+ 1 more updateAdamis Pharmaceuticals Corporation Announces Chief Financial Officer ChangesOn July 18, 2023, David C. Benedicto, the chief financial officer of Adamis Pharmaceuticals Corporation (Company), notified the company that he was tendering his resignation from the company effective July 21, 2023. The Company will commence a search for a new chief financial officer. In the interim, David J. Marguglio, the Company’s President and Chief Operating Officer, will assume the duties of chief financial officer of the Company on an interim basis until the company appoints a successor, and the board of directors of the Company has approved that appointment. Mr. Marguglio joined the Company as Vice President, Business Development and Investor Relations, and a director in April 2009, and was appointed as President and Chief Executive Officer of the Company in May 2022 and was Chief Executive Officer until the Company’s merger in May 2023 with DMK Pharmaceuticals Corporation. He has held positions with the Company of Senior Vice President of Corporate Development and, since March 2017, Senior Vice President and Chief Business Officer. Prior to Adamis, Mr. Marguglio held various positions with Citigroup Global Markets, Salomon Smith Barney and Merrill Lynch. Before entering the financial industry, he worked as a financial analyst and founded and ran two different startup companies, the latter of which was eventually acquired by a Fortune 100 company. He received a degree in finance and business management from the Hankamer School of Business at Baylor University.お知らせ • May 26Adamis Pharmaceuticals Corporation (NasdaqCM:ADMP) acquired DMK Pharmaceuticals, Inc. from Windhover Ventures LLC.Adamis Pharmaceuticals Corporation (NasdaqCM:ADMP) entered into an Agreement to acquire DMK Pharmaceuticals, Inc. from Windhover Ventures LLC on February 24, 2023. At the close of the merger, Eboo Versi, the current CEO of DMK, will assume the role of CEO and chairman of the combined company, David J. Marguglio, the current chief executive officer and President of Adamis, is expected to continue as President of the company and David C. Benedicto is expected to continue as the chief financial officer of the company. The transaction is subject to approval by the Adamis and DMK’s stockholders. The transaction was approved by the boards of directors of both companies and expected to close during the second quarter of 2023.Adamis Pharmaceuticals Corporation (NasdaqCM:ADMP) completed the acquisition of DMK Pharmaceuticals, Inc. from Windhover Ventures LLC on May 25, 2023. In connection with the merger, Ebrahim Versi assumed the role of Chief executive officer and Chairman of the Board and David J. Marguglio previously Chief Executive Officer of Adamis, will assume the role of President and Chief Operating Officer of the combined company. Ebrahim Versi and DMK board member Jannine Versi, have been appointed to the Board and join the pre-merger Adamis directors Howard C. Birndorf, Meera J. Desai, PhD, and Vickie Reed as the new Board of the combined company. Adamis Chairman, Richard C. Williams, and David J. Marguglio resigned their prior director roles in connection with the closing of the merger. Combined company will have commercial products and a library of development candidates, including two clinical stage programs.DPI-125, the lead development program, is a clinical stage therapeutic under investigation for the treatment of opioid use disorder.お知らせ • May 20+ 1 more updateAdamis Pharmaceuticals Corporation Contemplates Bankruptcy Adamis Pharmaceuticals Corporation is contemplating filing for bankruptcy, as of May 19, 2023. According to company press release, the managing director said that If we do not obtain required additional equity or debt funding in the near term, our cash resources will be depleted and we could be required to materially reduce or suspend operations, which would likely have a material adverse effect on our business, stock price and our relationships with third parties with whom we have business relationships, at least until additional funding is obtained. If we do not have sufficient funds to continue operations or satisfy out liabilities, we could be required to seek bankruptcy protection or other alternatives to attempt to resolve our obligations and liabilities that could result in our stockholders losing most or all their investment in us.お知らせ • May 09Adamis Pharmaceuticals Corporation to Report Q1, 2023 Results on May 15, 2023Adamis Pharmaceuticals Corporation announced that they will report Q1, 2023 results at 1:00 PM, Pacific Standard Time on May 15, 2023Board Change • Mar 04Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Howard Birndorf was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 23Third quarter 2021 earnings: EPS in line with expectations, revenues disappointThird quarter 2021 results: US$0.035 loss per share (up from US$0.10 loss in 3Q 2020). Revenue: US$760.0k (down 82% from 3Q 2020). Net loss: US$5.17m (loss narrowed 31% from 3Q 2020). Revenue missed analyst estimates by 9.4%. Over the next year, revenue is expected to shrink by 27% compared to a 19% growth forecast for the industry in the United Kingdom.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Howard Birndorf was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.株主還元0A4XGB PharmaceuticalsGB 市場7D0%-8.0%-1.7%1Y-99.8%22.1%16.3%株主還元を見る業界別リターン: 0A4X過去 1 年間で22.1 % の収益を上げたUK Pharmaceuticals業界を下回りました。リターン対市場: 0A4Xは、過去 1 年間で16.3 % のリターンを上げたUK市場を下回りました。価格変動Is 0A4X's price volatile compared to industry and market?0A4X volatility0A4X Average Weekly Movementn/aPharmaceuticals Industry Average Movement5.5%Market Average Movement5.3%10% most volatile stocks in GB Market10.6%10% least volatile stocks in GB Market2.8%安定した株価: 0A4Xの株価は、 UK市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間の0A4Xのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/a12Eddie Gloverwww.dmkpharmaceuticals.comDMKファーマシューティカルズ株式会社は、臨床段階にあるニューロバイオテクノロジー企業で、アレルギー、オピオイド過剰摂取、呼吸器、炎症性疾患の治療分野における製品を開発し、商業化している。同社の臨床段階の主要製品候補であるDPI-125は、オピオイド使用障害の治療に適応がある。同社の製品には、刺す・咬む昆虫、アレルゲン免疫療法、食品、医薬品、診断検査物質、その他のアレルゲンに対するアレルギー反応、特発性または運動誘発性アナフィラキシーの緊急治療用エピネフリン注射剤SYMJEPI、オピオイド過剰摂取治療用ナロキソン注射剤ZIMHIなどがある。以前はアダミス・ファーマシューティカルズ・コーポレーションとして知られていたが、2023年9月にDMKファーマシューティカルズ・コーポレーションに社名変更した。本社はカリフォルニア州サンディエゴ。2024年2月2日、DMKファーマシューティカルズコーポレーションは関連会社とともにデラウェア州連邦破産裁判所に連邦破産法第11条に基づく任意整理を申請した。もっと見るDMK Pharmaceuticals Corporation 基礎のまとめDMK Pharmaceuticals の収益と売上を時価総額と比較するとどうか。0A4X 基礎統計学時価総額US$10.00収益（TTM）-US$21.33m売上高(TTM)US$3.62m0.0xP/Sレシオ0.0xPER（株価収益率0A4X は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計0A4X 損益計算書（TTM）収益US$3.62m売上原価US$4.97m売上総利益-US$1.35mその他の費用US$19.98m収益-US$21.33m直近の収益報告Sep 30, 2023次回決算日該当なし一株当たり利益（EPS）-2.11グロス・マージン-37.30%純利益率-589.28%有利子負債／自己資本比率0%0A4X の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/11/20 00:51終値2024/10/08 00:00収益2023/09/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋DMK Pharmaceuticals Corporation 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Andrew D'SilvaB. Riley Securities, Inc.Jason KolbertH.C. Wainwright & Co.Jason KolbertMaxim Group2 その他のアナリストを表示
お知らせ • Sep 10Second Motion for Exclusivity Period Extension Approved For DMK Pharmaceuticals CorporationThe US Bankruptcy Court granted an order for the extension of the exclusivity period DMK Pharmaceuticals Corporation on September 9, 2024. As per the order, the debtor’s exclusivity period to solicit votes on its plan has been extended by 30 days i.e. up to October 31, 2024.
お知らせ • Aug 03Joint Liquidation Plan and Disclosure Statement Filed by DMK Pharmaceuticals CorporationDMK Pharmaceuticals Corporation, along with its affiliates, filed a joint plan of liquidation with related disclosure statement in the US Bankruptcy Court on August 2, 2024. As per the plan filed, administrative expense claims, fee claims, priority tax claims, U.S. Trustee fees, and priority non-tax claims of $979 shall be paid in full in cash. Allowed secured claims are of $0. Allowed unsecured claims of $25.34 million shall be recovered 3.4% i.e., $0.86 million pro rata share of distributions from liquidation trust assets as beneficiaries of the liquidation trust until they have received payment in full. Subordinated claims of $16.96 million shall not receive or retain any distribution under the plan. Equity interests will be extinguished on the effective date and shall not receive or retain any distribution under the plan. The plan shall be funded by the liquidation trust assets, other than the professional fees reserve. on the effective date, the debtors shall fund the professional fees reserve in full in cash.
お知らせ • Jun 15First Motion for Exclusivity Period Extension Approved For DMK Pharmaceuticals CorporationThe US Bankruptcy Court granted first order for the extension of the exclusivity periods for DMK Pharmaceuticals Corporation on June 14, 2024. As per the order, the debtor’s exclusivity period to file its plan and to solicit votes on its plan, have been extended by 60 days i.e., up to August 2, 2024, and October 1, 2024, respectively.
お知らせ • May 09Motion for Asset Sale Approved for DMK Pharmaceuticals CorporationThe US Bankruptcy Court gave an order approving the sale of substantially all the assets of DMK Pharmaceuticals Corporation on May 8, 2024. The debtor has been authorized to sell substantially all its assets to Zmi Management Inc for a purchase price of $3.17 million in cash. David R. Eastlake and Hans E. Biebl of Greenberg Traurig, LLP acted as legal advisors to the buyer.
お知らせ • Mar 22Nasdaq to Delist Common Stock of DMK PharmaceuticalsNasdaq announced that it will delist the common stock of DMK Pharmaceuticals Corporation. DMK Pharmaceuticals’s securities were suspended on February 7, 2024, and have not traded on Nasdaq since that time.
お知らせ • Feb 08DMK Pharmaceuticals Corporation(NasdaqCM:DMK) dropped from S&P TMI IndexDMK Pharmaceuticals Corporation(NasdaqCM:DMK) dropped from S&P TMI Index
お知らせ • Sep 10Second Motion for Exclusivity Period Extension Approved For DMK Pharmaceuticals CorporationThe US Bankruptcy Court granted an order for the extension of the exclusivity period DMK Pharmaceuticals Corporation on September 9, 2024. As per the order, the debtor’s exclusivity period to solicit votes on its plan has been extended by 30 days i.e. up to October 31, 2024.
お知らせ • Aug 03Joint Liquidation Plan and Disclosure Statement Filed by DMK Pharmaceuticals CorporationDMK Pharmaceuticals Corporation, along with its affiliates, filed a joint plan of liquidation with related disclosure statement in the US Bankruptcy Court on August 2, 2024. As per the plan filed, administrative expense claims, fee claims, priority tax claims, U.S. Trustee fees, and priority non-tax claims of $979 shall be paid in full in cash. Allowed secured claims are of $0. Allowed unsecured claims of $25.34 million shall be recovered 3.4% i.e., $0.86 million pro rata share of distributions from liquidation trust assets as beneficiaries of the liquidation trust until they have received payment in full. Subordinated claims of $16.96 million shall not receive or retain any distribution under the plan. Equity interests will be extinguished on the effective date and shall not receive or retain any distribution under the plan. The plan shall be funded by the liquidation trust assets, other than the professional fees reserve. on the effective date, the debtors shall fund the professional fees reserve in full in cash.
お知らせ • Jun 15First Motion for Exclusivity Period Extension Approved For DMK Pharmaceuticals CorporationThe US Bankruptcy Court granted first order for the extension of the exclusivity periods for DMK Pharmaceuticals Corporation on June 14, 2024. As per the order, the debtor’s exclusivity period to file its plan and to solicit votes on its plan, have been extended by 60 days i.e., up to August 2, 2024, and October 1, 2024, respectively.
お知らせ • May 09Motion for Asset Sale Approved for DMK Pharmaceuticals CorporationThe US Bankruptcy Court gave an order approving the sale of substantially all the assets of DMK Pharmaceuticals Corporation on May 8, 2024. The debtor has been authorized to sell substantially all its assets to Zmi Management Inc for a purchase price of $3.17 million in cash. David R. Eastlake and Hans E. Biebl of Greenberg Traurig, LLP acted as legal advisors to the buyer.
お知らせ • Mar 22Nasdaq to Delist Common Stock of DMK PharmaceuticalsNasdaq announced that it will delist the common stock of DMK Pharmaceuticals Corporation. DMK Pharmaceuticals’s securities were suspended on February 7, 2024, and have not traded on Nasdaq since that time.
お知らせ • Feb 08DMK Pharmaceuticals Corporation(NasdaqCM:DMK) dropped from S&P TMI IndexDMK Pharmaceuticals Corporation(NasdaqCM:DMK) dropped from S&P TMI Index
お知らせ • Feb 07DMK Pharmaceuticals Corporation(OTCPK:DMKP.Q) dropped from NASDAQ Composite IndexDMK Pharmaceuticals Corporation has been dropped from Nasdaq Composite Index.
お知らせ • Jan 06DMK Pharmaceuticals Corporation, Annual General Meeting, Jan 25, 2024DMK Pharmaceuticals Corporation, Annual General Meeting, Jan 25, 2024, at 09:00 Pacific Standard Time.
お知らせ • Nov 29DMK Pharmaceuticals Corporation Regains Full Rights from US WorldMeds for SYMJEPIDMK Pharmaceuticals Corporation announced that it is reacquiring the rights to its SYMJEPI (epinephrine) Injection 0.3mg and SYMJEPI (epinephrine) Injection 0.15mg products from USWM, LLC (“USWM” or “US WorldMeds”). US WorldMeds previously held exclusive distribution and commercialization rights for SYMJEPI and ZIMHI (naloxone) products in the United States, and was responsible for marketing, promotion and distribution efforts. The Company is now actively seeking out-license opportunities for SYMJEPI in the US and globally, in addition to exploring other options with a focus on maximizing value for shareholders.
お知らせ • Nov 22Adamis Pharmaceuticals Corporation(NasdaqCM:ADMP) dropped from NASDAQ Composite IndexAdamis Pharmaceuticals Corporation has been dropped from NASDAQ Composite Index.
お知らせ • Oct 21DMK Pharmaceuticals Corporation Receives a Superseding Notice from the Listing Qualifications Department of the Nasdaq Stock MarketOn October 18, 2023, DMK Pharmaceuticals Corporation received a superseding notice from the Staff, indicating that the Prior Notice was issued in error. The Subsequent Notice indicated that because the Company was subject to a one-year Mandatory Panel Monitor as a result of a prior hearing before the Panel, the Company was not eligible for the automatic 180-day compliance grace period provided by Listing Rule 5810(c)(3)(A) and that the Company's non-compliance with the Bid Price Rule serves as an additional basis for delisting from Nasdaq. At the hearing, the Company will address its plan to regain compliance with both the Bid Price Rule and the MVLS Rule as well as its continued compliance with all other applicable criteria for continued listing on The Nasdaq Capital Market. There can be no assurance, however, that the Panel will grant the Company's request for continued listing or that the Company will evidence compliance with the listing rules prior to the expiration of any extension that may be granted by the Panel following the hearing.
お知らせ • Oct 20+ 1 more updateDMK Pharmaceuticals Corporation Announces CFO ChangesDMK Pharmaceuticals Corporation announced a series of management changes to optimize its leadership structure. Seth Cohen has been appointed as Chief Financial Officer and John Dorbin will assume the position of General Counsel Corporate Secretary. Mr. Cohen will be succeeding the outgoing interim CFO and President and Chief Operating Officer, David Marguglio. These organizational changes will be effective immediately. The new team is tasked with operating a lean and effective organization committed to increasing the sales of DMK’s existing commercial products and advancing its clinical pipeline. Mr. Cohen has over thirty years of experience in business and finance. Since 2011, Mr. Cohen has been a principal at CFOX Consulting, LLC, an advisory firm that specializes in CFO and related services for public, private equity backed, and start-up businesses. From 2000 to 2011, Mr. Cohen served in various leadership roles of increasing responsibility at Newtek Business Services Inc. In 2007, he was appointed CFO and tasked with directing the corporate accounting and finance department as well as overseeing the company’s various subsidiaries. Prior to that, Mr. Cohen served as Director of the Mayor’s Office of Pensions and Public Finance for the City of New York where he managed the securitization of assets, oversaw multibillion-dollar debt issuances, and initiated and helped oversee pension policy. As a trustee for the City of New York’s five pension systems, Mr. Cohen oversaw $100 billion in assets. He developed his corporate and municipal finance skills at Lehman Brothers, Patricof & Co., and Dean Witter Reynolds Inc. Mr. Cohen holds an MBA from Columbia Business School and a B.A. from Yale University.
お知らせ • Oct 18DMK Pharmaceuticals Corporation Receives Notice from the Listing Qualifications Staff of the Nasdaq Stock MarketAs previously disclosed, on April 12, 2023, DMK Pharmaceuticals Corporation received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC stating that the market value of the Company’s common stock closed below the minimum $35 million threshold required by Nasdaq Listing Rule 5550(b)(2) for the previous 30 consecutive trading days and, in accordance with the Nasdaq Listing Rules, the Company was provided 180 calendar days, or until October 9, 2023, to regain compliance with the Rule. On October 11, 2023, the Company received notice from the Staff that the Company’s common stock was subject to delisting unless the Company timely requests a hearing before the Nasdaq Hearings Panel. The Company plans to timely request a hearing before the Panel, which request will stay any further action by Nasdaq at least until the hearing is held and any extension the Panel may grant to the Company following the hearing expires. There can be no assurance, however, that the Panel will grant the Company’s request for continued listing or that the Company will regain compliance with the Rule prior to the expiration of any extension that may be granted to the Company following the hearing.
お知らせ • Oct 11DMK Pharmaceuticals Receives Notice from the Listing Qualifications Department of the Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price RequirementsOn October 4, 2023, DMK Pharmaceuticals Corporation received a notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that it is not in compliance with the $1.00 minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”) for continued listing on The Nasdaq Capital Market. Based on the closing bid price of the Company’s common stock for at least 30 consecutive business days before receipt of the Notice, the Company no longer meets the minimum bid price requirement of the Rule. This notice has no immediate effect on the Company’s Nasdaq listing or the trading of its common stock. The Notice indicated that the Nasdaq Listing Rules provide the Company a compliance period of 180 calendar days from the date of the Notice, or until April 1, 2024, to regain compliance, pursuant to Listing Rule 5810(c)(3)(A). The Notice stated that if at any time during the compliance period the bid price of the Company’s common stock closes at or above $1.00 per share for a minimum of 10 consecutive business days, the Staff will provide written notification that the Company has achieved compliance with the minimum bid price requirement, and the matter would be resolved. The Notice also stated that if the Company does not regain compliance within the initial compliance period, it may be eligible for an additional 180-day compliance period. To qualify for additional time, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and would need to provide written notice of its intention to cure the deficiency during the second compliance period. The Notice stated that if the Company meets these requirements, Nasdaq will inform the Company that it has been granted an additional 180 calendar days to regain compliance. The Notice also stated that if it appears to the Staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, the Staff would notify the Company that it will not be granted additional 180 days for compliance and will be subject to delisting at that time. In the event of such notification, the Company may appeal the Staff’s determination to delist its securities, but there can be no assurance that any such appeal would be successful. There are no assurances that the Company will be able to regain compliance with the Rule or will otherwise be in compliance with other Nasdaq listing requirements.
お知らせ • Sep 02Adamis Pharmaceuticals Corporation, Annual General Meeting, Nov 09, 2023Adamis Pharmaceuticals Corporation, Annual General Meeting, Nov 09, 2023.
お知らせ • Aug 06Adamis Pharmaceuticals Corporation has completed a Composite Units Offering in the amount of $8.005387 million.Adamis Pharmaceuticals Corporation has completed a Composite Units Offering in the amount of $8.005387 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 4,800,000 Price\Range: $1.35 Discount Per Security: $0.0945 Security Name: Pre-Funded Units Security Type: Equity/Derivative Unit Securities Offered: 1,130,000 Price\Range: $1.3499 Discount Per Security: $0.09449
お知らせ • Jul 26+ 1 more updateAdamis Pharmaceuticals Corporation Announces Chief Financial Officer ChangesOn July 18, 2023, David C. Benedicto, the chief financial officer of Adamis Pharmaceuticals Corporation (Company), notified the company that he was tendering his resignation from the company effective July 21, 2023. The Company will commence a search for a new chief financial officer. In the interim, David J. Marguglio, the Company’s President and Chief Operating Officer, will assume the duties of chief financial officer of the Company on an interim basis until the company appoints a successor, and the board of directors of the Company has approved that appointment. Mr. Marguglio joined the Company as Vice President, Business Development and Investor Relations, and a director in April 2009, and was appointed as President and Chief Executive Officer of the Company in May 2022 and was Chief Executive Officer until the Company’s merger in May 2023 with DMK Pharmaceuticals Corporation. He has held positions with the Company of Senior Vice President of Corporate Development and, since March 2017, Senior Vice President and Chief Business Officer. Prior to Adamis, Mr. Marguglio held various positions with Citigroup Global Markets, Salomon Smith Barney and Merrill Lynch. Before entering the financial industry, he worked as a financial analyst and founded and ran two different startup companies, the latter of which was eventually acquired by a Fortune 100 company. He received a degree in finance and business management from the Hankamer School of Business at Baylor University.
お知らせ • May 26Adamis Pharmaceuticals Corporation (NasdaqCM:ADMP) acquired DMK Pharmaceuticals, Inc. from Windhover Ventures LLC.Adamis Pharmaceuticals Corporation (NasdaqCM:ADMP) entered into an Agreement to acquire DMK Pharmaceuticals, Inc. from Windhover Ventures LLC on February 24, 2023. At the close of the merger, Eboo Versi, the current CEO of DMK, will assume the role of CEO and chairman of the combined company, David J. Marguglio, the current chief executive officer and President of Adamis, is expected to continue as President of the company and David C. Benedicto is expected to continue as the chief financial officer of the company. The transaction is subject to approval by the Adamis and DMK’s stockholders. The transaction was approved by the boards of directors of both companies and expected to close during the second quarter of 2023.Adamis Pharmaceuticals Corporation (NasdaqCM:ADMP) completed the acquisition of DMK Pharmaceuticals, Inc. from Windhover Ventures LLC on May 25, 2023. In connection with the merger, Ebrahim Versi assumed the role of Chief executive officer and Chairman of the Board and David J. Marguglio previously Chief Executive Officer of Adamis, will assume the role of President and Chief Operating Officer of the combined company. Ebrahim Versi and DMK board member Jannine Versi, have been appointed to the Board and join the pre-merger Adamis directors Howard C. Birndorf, Meera J. Desai, PhD, and Vickie Reed as the new Board of the combined company. Adamis Chairman, Richard C. Williams, and David J. Marguglio resigned their prior director roles in connection with the closing of the merger. Combined company will have commercial products and a library of development candidates, including two clinical stage programs.DPI-125, the lead development program, is a clinical stage therapeutic under investigation for the treatment of opioid use disorder.
お知らせ • May 20+ 1 more updateAdamis Pharmaceuticals Corporation Contemplates Bankruptcy Adamis Pharmaceuticals Corporation is contemplating filing for bankruptcy, as of May 19, 2023. According to company press release, the managing director said that If we do not obtain required additional equity or debt funding in the near term, our cash resources will be depleted and we could be required to materially reduce or suspend operations, which would likely have a material adverse effect on our business, stock price and our relationships with third parties with whom we have business relationships, at least until additional funding is obtained. If we do not have sufficient funds to continue operations or satisfy out liabilities, we could be required to seek bankruptcy protection or other alternatives to attempt to resolve our obligations and liabilities that could result in our stockholders losing most or all their investment in us.
お知らせ • May 09Adamis Pharmaceuticals Corporation to Report Q1, 2023 Results on May 15, 2023Adamis Pharmaceuticals Corporation announced that they will report Q1, 2023 results at 1:00 PM, Pacific Standard Time on May 15, 2023
Board Change • Mar 04Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Howard Birndorf was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 23Third quarter 2021 earnings: EPS in line with expectations, revenues disappointThird quarter 2021 results: US$0.035 loss per share (up from US$0.10 loss in 3Q 2020). Revenue: US$760.0k (down 82% from 3Q 2020). Net loss: US$5.17m (loss narrowed 31% from 3Q 2020). Revenue missed analyst estimates by 9.4%. Over the next year, revenue is expected to shrink by 27% compared to a 19% growth forecast for the industry in the United Kingdom.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Howard Birndorf was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
